NxStage Medical (NXTM) Rating Lowered to Sell at Zacks Investment Research

NxStage Medical (NASDAQ:NXTM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

Other equities research analysts have also issued reports about the company. Northland Securities restated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research note on Wednesday, November 8th. Canaccord Genuity restated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research note on Tuesday, October 17th. BidaskClub upgraded NxStage Medical from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Finally, ValuEngine lowered NxStage Medical from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. NxStage Medical presently has a consensus rating of “Hold” and an average target price of $30.25.

Shares of NxStage Medical (NASDAQ:NXTM) opened at $23.31 on Tuesday. NxStage Medical has a 12 month low of $20.45 and a 12 month high of $30.80.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $25.35, for a total transaction of $88,725.00. Following the completion of the sale, the senior vice president now directly owns 14,270 shares in the company, valued at $361,744.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 10,500 shares of company stock valued at $265,860 over the last 90 days. 4.70% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado acquired a new stake in shares of NxStage Medical in the fourth quarter valued at about $128,000. Prudential Financial Inc. acquired a new stake in shares of NxStage Medical in the third quarter valued at about $202,000. Amalgamated Bank grew its stake in shares of NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after buying an additional 553 shares in the last quarter. Athos Capital Ltd acquired a new stake in shares of NxStage Medical in the third quarter valued at about $557,000. Finally, Suntrust Banks Inc. grew its stake in shares of NxStage Medical by 2.3% in the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after buying an additional 209 shares in the last quarter. Institutional investors and hedge funds own 84.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/nxstage-medical-nxtm-rating-lowered-to-sell-at-zacks-investment-research.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply